



Healionics' Andrew Marshall to be Awarded the Innovation/Commercialization Award at the TERMIS World Congress

Seattle, WA (August 20, 2012) — Healionics' Chief Technology Officer, Andrew Marshall, PhD, has been chosen as the recipient of the 2012 Innovation/Commercialization Award by TERMIS-Americas, the western hemisphere chapter of the Tissue Engineering and Regenerative Medicine International Society.

The Innovation/Commercialization Award recognizes the application of tissue engineering and regenerative medicine in the production of a product or technology that ultimately will benefit patients. The award will be presented at the 3rd TERMIS World Congress 2012, held in Vienna, Austria September 5-8.

In addition to receiving the award, Dr. Marshall's abstract titled "An Infection Control Solution for Catheter Exit Sites: Translation from Mice to Device" has been selected for oral presentation at the TERMIS World Congress. The talk will discuss Healionics' approach to commercializing STARcuff™, an infection-resistant porous exit site sleeve for skin-breaching devices. Results demonstrating long-term anti-infection performance will be presented.

"I'm extremely pleased to receive this award," says Marshall, "The efforts of the entire Healionics team, including our subsidiaries, iSTAR Medical and qSTAR Medical, made this international recognition possible by bringing the innovative STARflo™ glaucoma implant to patients and developing infection-resistant percutaneous devices using STARcuff™."

More about the TERMIS Awards can be found at http://termis.org/chapters_na_awards.php.

The list of 2012 Awardees can be found at http://termis.org/chapters_na_awards.php?y=2012.

More information about the TERMIS World Congress can be found at <http://www.wc2012-vienna.org>.

About Healionics Corporation

Healionics develops and manufactures STAR® Biomaterials for implanted medical devices. The precisely controlled pore structure of the innovative STAR technology induces a favorable integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity. www.healionics.com

###

Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com